BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-1010. [PMID: 16525137 DOI: 10.1056/nejmoa051285] [Cited by in Crossref: 1014] [Cited by in F6Publishing: 327] [Article Influence: 67.6] [Reference Citation Analysis]
Number Citing Articles
1 Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH;  American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283. [PMID: 26566064 DOI: 10.1002/hep.28156] [Cited by in Crossref: 1159] [Cited by in F6Publishing: 1064] [Article Influence: 193.2] [Reference Citation Analysis]
2 Kim JT, Jeong HW, Choi KH, Yoon TY, Sung N, Choi YK, Kim EH, Chae HB. Delayed hypersensitivity reaction resulting in maculopapular-type eruption due to entecavir in the treatment of chronic hepatitis B. World J Gastroenterol 2014; 20(42): 15931-15936 [PMID: 25400481 DOI: 10.3748/wjg.v20.i42.15931] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
3 Khungar V, Han SH. A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B. Curr Hepat Rep 2010;9:75-90. [PMID: 20461127 DOI: 10.1007/s11901-010-0039-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
4 Zoulim F. Emerging drugs for hepatitis B. Expert Opin Emerg Drugs 2007;12:199-217. [PMID: 17604497 DOI: 10.1517/14728214.12.2.199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
5 Wong WW, Woo G, Heathcote EJ, Krahn M. Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol 2013;27:137-47. [PMID: 23516678 DOI: 10.1155/2013/924640] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
6 Schiffer JT, Aubert M, Weber ND, Mintzer E, Stone D, Jerome KR. Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol. 2012;86:8920-8936. [PMID: 22718830 DOI: 10.1128/jvi.00052-12] [Cited by in Crossref: 85] [Cited by in F6Publishing: 54] [Article Influence: 9.4] [Reference Citation Analysis]
7 Zhang QQ, An X, Liu YH, Li SY, Zhong Q, Wang J, Hu HD, Zhang DZ, Ren H, Hu P. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J. 2011;8:72. [PMID: 21324130 DOI: 10.1186/1743-422x-8-72] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
8 Kim SB, Song IH, Kim YM, Noh R, Kang HY, Lee HI, Yang HY, Kim AN, Chae HB, Lee SH, Kim HS, Lee TH, Kang YW, Lee ES, Kim SH, Lee BS, Lee HY. Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B. World J Gastroenterol 2012; 18(47): 6943-6950 [PMID: 23322992 DOI: 10.3748/wjg.v18.i47.6943] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
9 Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. Cancer Sci 2021;112:1943-54. [PMID: 33576088 DOI: 10.1111/cas.14846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Lin PF, Nowicka-Sans B, Terry B, Zhang S, Wang C, Fan L, Dicker I, Gali V, Higley H, Parkin N, Tenney D, Krystal M, Colonno R. Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. Antimicrob Agents Chemother 2008;52:1759-67. [PMID: 18316521 DOI: 10.1128/AAC.01313-07] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
11 李志强, 何玉霞, 耿建洪, 姜清河, 刘军, 张凤艳. 聚乙二醇α干扰素对慢性乙型肝炎患者血清IFN-γ、IL-17、IL-10的影响作用及机制. 世界华人消化杂志 2016; 24(1): 116-120 [DOI: 10.11569/wcjd.v24.i1.116] [Reference Citation Analysis]
12 Keating GM. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs. 2011;71:2511-2529. [PMID: 22141390 DOI: 10.2165/11208510-000000000-00000] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
13 Ren FY, Jin H, Piao XX, Piao FS. Ribavirin and IFN-α combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B. World J Gastroenterol 2007; 13(41): 5440-5445 [PMID: 17907286 DOI: 10.3748/wjg.v13.i41.5440] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
14 Shin JW, Jeong J, Jung SW, Lee SB, Park BR, Kim MJ, Park EJ, Park NH. Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Dig Dis Sci 2021;66:1739-50. [PMID: 32524416 DOI: 10.1007/s10620-020-06375-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Hasosah MY, Ghandourah HS, Alsahafi AF, Sukkar GA, Jacobson K. Seroconversion of hepatitis B envelope antigen (HBeAg) by entecavir in a child with chronic hepatitis B. Saudi J Gastroenterol 2012;18:217-20. [PMID: 22626803 DOI: 10.4103/1319-3767.96465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Malik R, Kennedy P, Suri D, Brown A, Goldin R, Main J, Thomas H, Thursz M. The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience. Hepat Res Treat 2011;2011:524027. [PMID: 22114737 DOI: 10.1155/2011/524027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
17 Chen YC, Jeng WJ, Hsu CW, Lin CY. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. BMC Gastroenterol 2020;20:146. [PMID: 32397963 DOI: 10.1186/s12876-020-01289-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. PLoS One. 2015;10:e0122259. [PMID: 25835020 DOI: 10.1371/journal.pone.0122259] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
19 Muqit MK, Stanga PE, Vilar FJ, Patton N. Presumed entecavir-induced ocular toxicity. Eye (Lond) 2011;25:1665-8. [PMID: 22020173 DOI: 10.1038/eye.2011.259] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 Li P, Geng J, Li W, Xu X, Zhang X, Zheng W, Yu Y, Yang Z, Wang M. Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants. Virol J 2017;14:68. [PMID: 28376852 DOI: 10.1186/s12985-017-0739-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283x1245024510.1177_1756283x12450245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Kim KH, Kim ND, Seong BL. Discovery and development of anti-HBV agents and their resistance. Molecules. 2010;15:5878-5908. [PMID: 20802402 DOI: 10.3390/molecules15095878] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
23 Gui HL, Zhao CQ, Wang Y, Gu HT, Wang WJ, Cai W, Guo Q, Bao SS, Xu LM, Xie Q. Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis. J Clin Transl Hepatol 2020;8:277-84. [PMID: 33083250 DOI: 10.14218/JCTH.2020.00004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Jun DW, Kim BI, Cho YK, Kim HJ, Kwon YO, Park SY, Han SY, Baek YH, Jung YJ, Kim HY, Kim W, Heo J, Woo HY, Hwang SG, Rim KS, Choi JY, Bae SH, Lee YS, Lim YS, Cheong JY, Cho SW, Lee BS, Kim SH, Sohn JH, Kim TY, Paik YH, Kim JK, Lee KS. Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study. Clin Mol Hepatol 2013;19:165-72. [PMID: 23837141 DOI: 10.3350/cmh.2013.19.2.165] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
25 Scott LJ, Keating GM. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2009;69:1003-1033. [PMID: 19496629 DOI: 10.2165/00003495-200969080-00005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
26 De Pasquale C, Campana S, Barberi C, Sidoti Migliore G, Oliveri D, Lanza M, Musolino C, Raimondo G, Ferrone S, Pollicino T, Ferlazzo G. Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells. Hepatology 2021;74:550-65. [PMID: 33482027 DOI: 10.1002/hep.31725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M. Hepatitis B in patients with hematological diseases: An update. World J Hepatol 2017; 9(25): 1043-1053 [PMID: 28951776 DOI: 10.4254/wjh.v9.i25.1043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
28 Yeh CT, Chen T, Hsu CW, Chen YC, Lai MW, Liang KH, Chen TC. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer. 2011;11:398. [PMID: 21933446 DOI: 10.1186/1471-2407-11-398] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
29 Miyauchi T, Kanda T, Shinozaki M, Kamezaki H, Wu S, Nakamoto S, Kato K, Arai M, Mikami S, Sugiura N. Efficacy of lamivudine or entecavir against virological rebound after achieving HBV DNA negativity in chronic hepatitis B patients. Int J Med Sci. 2013;10:647-652. [PMID: 23569428 DOI: 10.7150/ijms.5904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
30 Wang JL, Du XF, Chen SL, Yu YQ, Wang J, Hu XQ, Shao LY, Chen JZ, Weng XH, Zhang WH. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy. World J Gastroenterol 2015; 21(32): 9598-9606 [PMID: 26327767 DOI: 10.3748/wjg.v21.i32.9598] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
31 Jiang L, Yan LN. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol 2010; 16(20): 2468-2475 [PMID: 20503446 DOI: 10.3748/wjg.v16.i20.2468] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
32 Zhang H, Huo M, Chao J, Liu P. Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B. PLoS One 2016;11:e0161936. [PMID: 27574976 DOI: 10.1371/journal.pone.0161936] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
33 Xu Y, Wu XN, Shi YW, Wei W, Yang AT, Sun YM, Zhao WS, You H. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis. Chin Med J (Engl) 2015;128:1867-72. [PMID: 26168824 DOI: 10.4103/0366-6999.160488] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
34 Yoshida K, Murata M, Yamaguchi T, Matsuzaki K. TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review). Int J Oncol 2014;45:1363-71. [PMID: 25050845 DOI: 10.3892/ijo.2014.2552] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 10.9] [Reference Citation Analysis]
35 Yoon J, Park D, Kim C. A granulomatous drug eruption induced by entecavir. Ann Dermatol 2013;25:493-5. [PMID: 24371400 DOI: 10.5021/ad.2013.25.4.493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
36 Lu HY, Zhuang LW, Yu YY, Si CW, Li J, Zhang JJ, Zeng Z, Chen XY, Han ZH, Chen Y. Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol 2008; 14(8): 1268-1273 [PMID: 18300356 DOI: 10.3748/wjg.14.1268] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
37 Chen YC, Hsu CW, Chang MY, Yeh CT. On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study. BMC Res Notes. 2013;6:349. [PMID: 24004574 DOI: 10.1186/1756-0500-6-349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
38 Shen S, Jiang L, Xiao GQ, Yan LN, Yang JY, Wen TF, Li B, Wang WT, Xu MQ, Wei YG. Prophylaxis against hepatitis B virus recurrence after liver transplantation: A registry study. World J Gastroenterol 2015; 21(2): 584-592 [PMID: 25593480 DOI: 10.3748/wjg.v21.i2.584] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
39 Kim EH, Park H, Lee KH, Ahn SH, Kim SM, Han KH. Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. Clin Mol Hepatol 2013;19:82-6. [PMID: 23593614 DOI: 10.3350/cmh.2013.19.1.82] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
40 Lee SB, Jeong J, Park JH, Jung SW, Jeong ID, Bang SJ, Shin JW, Park BR, Park EJ, Park NH. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol 2020;26:364-75. [PMID: 32466635 DOI: 10.3350/cmh.2020.0012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
41 Wong DK, Tanaka Y, Lai CL, Mizokami M, Fung J, Yuen MF. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol. 2007;45:3942-3947. [PMID: 17942661 DOI: 10.1128/jcm.00366-07] [Cited by in Crossref: 108] [Cited by in F6Publishing: 41] [Article Influence: 7.7] [Reference Citation Analysis]
42 Vilarinho S, Ogasawara K, Nishimura S, Lanier LL, Baron JL. Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc Natl Acad Sci USA. 2007;104:18187-18192. [PMID: 17991774 DOI: 10.1073/pnas.0708968104] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 6.2] [Reference Citation Analysis]
43 Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-11. [PMID: 17178796 DOI: 10.1128/AAC.00833-06] [Cited by in Crossref: 172] [Cited by in F6Publishing: 50] [Article Influence: 11.5] [Reference Citation Analysis]
44 Kim DY, Chang HY, Lim SM, Kim SU, Park JY, Kim JK, Lee KS, Han KH, Chon CY, Ahn SH. Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B. Gut Liver 2013;7:329-34. [PMID: 23710315 DOI: 10.5009/gnl.2013.7.3.329] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
45 Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007;20:426-439, table of contents. [PMID: 17630333 DOI: 10.1128/cmr.00009-07] [Cited by in Crossref: 86] [Cited by in F6Publishing: 32] [Article Influence: 6.1] [Reference Citation Analysis]
46 Chung WG, Kim HJ, Choe YG, Seok HS, Chon CW, Cho YK, Kim BI, Koh YY. Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection. Clin Mol Hepatol 2012;18:195-202. [PMID: 22893870 DOI: 10.3350/cmh.2012.18.2.195] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
47 Matsumoto K, Miyake Y, Miyatake H, Takahara M, Imada T, Yagi S, Toyokawa T, Nakatsu M, Ando M, Hirohata M. A combination treatment of entecavir and early-phase corticosteroid in severe exacerbation of chronic hepatitis B. World J Gastroenterol 2009; 15(13): 1650-1652 [PMID: 19340912 DOI: 10.3748/wjg.15.1650] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
48 Langley DR, Walsh AW, Baldick CJ, Eggers BJ, Rose RE, Levine SM, Kapur AJ, Colonno RJ, Tenney DJ. Inhibition of hepatitis B virus polymerase by entecavir. J Virol. 2007;81:3992-4001. [PMID: 17267485 DOI: 10.1128/jvi.02395-06] [Cited by in Crossref: 125] [Cited by in F6Publishing: 60] [Article Influence: 8.9] [Reference Citation Analysis]
49 Luo A, Jiang X, Ren H. Entecavir-based combination therapies for chronic hepatitis B: A meta-analysis. Medicine (Baltimore) 2018;97:e13596. [PMID: 30572464 DOI: 10.1097/MD.0000000000013596] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Lau GK, Leung N. Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study. Korean J Hepatol. 2010;16:315-320. [PMID: 20924215 DOI: 10.3350/kjhep.2010.16.3.315] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
51 Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680-1686. [PMID: 19632234 DOI: 10.53/j.gastro.2009.07.047] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Sonneveld MJ, Janssen HL. Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Curr Hepat Rep. 2010;9:91-98. [PMID: 20461129 DOI: 10.1007/s11901-010-0041-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
53 Chao DC, Hu KQ. Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther. 2013;7:777-788. [PMID: 23990707 DOI: 10.2147/dddt.s33947] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
54 Hsu CW, Chu YD, Lai MW, Lin CL, Liang KH, Lin YH, Yeh CT. Hepatitis B Virus Covalently Closed Circular DNA Predicts Postoperative Liver Cancer Metastasis Independent of Virological Suppression. Cancers (Basel) 2021;13:538. [PMID: 33572617 DOI: 10.3390/cancers13030538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Yildiz UH, Inci F, Wang S, Toy M, Tekin HC, Javaid A, Lau DT, Demirci U. Recent advances in micro/nanotechnologies for global control of hepatitis B infection. Biotechnol Adv 2015;33:178-90. [PMID: 25450190 DOI: 10.1016/j.biotechadv.2014.11.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
56 Tang H, Griffin J, Innaimo S, Lehman-Mckeeman L, Llamoso C. The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2013;1:51-8. [PMID: 26357607 DOI: 10.14218/JCTH.2013.00006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
57 Li YH, Xu Y, Wu HM, Yang J, Yang LH, Yue-Meng W. Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation in Hepatitis B Virus Related Acute-on-Chronic Liver Failure Treated with Plasma Exchange and Entecavir: a 24-Month Prospective Study. Stem Cell Rev Rep. 2016;12:645-653. [PMID: 27687792 DOI: 10.1007/s12015-016-9683-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
58 Chang TT, Suh DJ. Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. Hepatol Int 2008;2:19-27. [PMID: 19669295 DOI: 10.1007/s12072-008-9059-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
59 Zheng X, Wang J, Yang D. Antiviral therapy for chronic hepatitis B in China. Med Microbiol Immunol 2015;204:115-20. [PMID: 25540038 DOI: 10.1007/s00430-014-0380-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
60 Matthews GV, Ali RJ, Avihingsanon A, Amin J, Hammond R, Bowden S, Lewin SR, Sasadeusz J, Littlejohn M, Locarnini SL, Ruxrungtham K, Dore GJ. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals. PLoS One 2013;8:e61297. [PMID: 23593455 DOI: 10.1371/journal.pone.0061297] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
61 Guan R, Lui HF. Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol. 2011;2011:918017. [PMID: 21994876 DOI: 10.4061/2011/918017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
62 Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, Katzarov K, Simonova M, Zeuzem S, Woffendin C, Chen PJ, Peng CY, Chang TT, Lueth S, De Knegt R, Choi MS, Wedemeyer H, Dao M, Kim CW, Chu HC, Wind-Rotolo M, Williams R, Cooney E, Chokshi S. Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Front Immunol 2017;8:621. [PMID: 28611778 DOI: 10.3389/fimmu.2017.00621] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
63 Kim YM, Shin HP, Lee JI, Joo KR, Cha JM, Jeon JW, Yoon JY, Kwak MS. Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B. Saudi J Gastroenterol 2018;24:326-35. [PMID: 30004042 DOI: 10.4103/sjg.SJG_49_18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
64 Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, Xu D, Jiang Z, Liu J, Xu D. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int. 2007;1:365-372. [PMID: 19669331 DOI: 10.1007/s12072-007-9009-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
65 Cho WH, Lee HJ, Bang KB, Kim SB, Song IH. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature. World J Gastroenterol 2018; 24(17): 1919-1924 [PMID: 29740207 DOI: 10.3748/wjg.v24.i17.1919] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
66 Wang FY, Li B, Li Y, Liu H, Qu WD, Xu HW, Qi JN, Qin CY. Entecavir for Patients with Hepatitis B Decompensated Cirrhosis in China: a meta-analysis. Sci Rep. 2016;6:32722. [PMID: 27601086 DOI: 10.1038/srep32722] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
67 Tong MJ, Pan CQ, Hann HW, Kowdley KV, Han SH, Min AD, Leduc TS. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci. 2011;56:3143-3162. [PMID: 21935699 DOI: 10.1007/s10620-011-1841-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
68 Abdel-Hady M, Kelly D. Chronic hepatitis B in children and adolescents: epidemiology and management. Paediatr Drugs 2013;15:311-7. [PMID: 23529864 DOI: 10.1007/s40272-013-0010-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
69 Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2008;2:163-78. [PMID: 19669301 DOI: 10.1007/s12072-008-9061-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
70 Lam YF, Yuen MF, Seto WK, Lai CL. Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Curr Hepat Rep. 2011;10:235-243. [PMID: 22131901 DOI: 10.1007/s11901-011-0109-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
71 Chang BW, Kaung A, Robbins L, Tran TT. Hepatitis B: Working Towards a Cure. Curr Gastroenterol Rep 2015;17:35. [PMID: 26275560 DOI: 10.1007/s11894-015-0460-2] [Reference Citation Analysis]
72 Toy M, Hutton DW, So SK. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS One 2015;10:e0139876. [PMID: 26536626 DOI: 10.1371/journal.pone.0139876] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
73 Pereira CV, Tovo CV, Grossmann TK, Mirenda H, Dal-Pupo BB, Almeida PR, Mattos AA. Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil. Mem Inst Oswaldo Cruz 2016;111:252-7. [PMID: 27074254 DOI: 10.1590/0074-02760150390] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
74 Ghaziani T, Sendi H, Shahraz S, Zamor P, Bonkovsky HL. Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome. World J Gastroenterol 2014; 20(39): 14142-14155 [PMID: 25339803 DOI: 10.3748/wjg.v20.i39.14142] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
75 Ghany MG, Feld JJ, Zhao X, Heller T, Doo E, Rotman Y, Nagabhyru P, Koh C, Kleiner DE, Wright EC, Liang TJ, Hoofnagle JH. Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. Aliment Pharmacol Ther 2012;35:1027-35. [PMID: 22449251 DOI: 10.1111/j.1365-2036.2012.05059.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 0.2] [Reference Citation Analysis]
76 Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev 2019;8:207. [PMID: 31426837 DOI: 10.1186/s13643-019-1126-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
77 Nagao Y, Kimura T, Nagao H. Analysis of hepatitis B and C virus infections amongst members of the Dental National Health Insurance Society in the Oita Prefecture. Biomed Rep 2021;14:23. [PMID: 33335729 DOI: 10.3892/br.2020.1399] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Sherman M, Lee SS. Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change. Can J Gastroenterol 2011;25:538-41. [PMID: 22059156 DOI: 10.1155/2011/864046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
79 Lee HS, Yoo BC, Lee KS, Kim JH, Um SH, Ryu SH, Lee YS, Kim YS, Yoo K, Han JY. Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy. J Gastroenterol. 2011;46:410-414. [PMID: 21181212 DOI: 10.1007/s00535-010-0354-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
80 Yang J, Sun H, Liu Q. The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2016;2016:5802674. [PMID: 27148364 DOI: 10.1155/2016/5802674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
81 Niu JX, Xu Y, Wu DP. [Progress in the research of HBV reactivation in patients undergoing hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2021;42:348-52. [PMID: 33979984 DOI: 10.3760/cma.j.issn.0253-2727.2021.04.016] [Reference Citation Analysis]
82 Tong MJ, Pan CQ, Han SB, Lu DS, Raman S, Hu KQ, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Aliment Pharmacol Ther 2018;47:1181-200. [PMID: 29479728 DOI: 10.1111/apt.14577] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
83 Saikia N, Talukdar R, Mazumder S, Khanna S, Tandon R. Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J. 2007;83:32-39. [PMID: 17267676 DOI: 10.1136/pgmj.2006.044826] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
84 Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008;2:284-95. [PMID: 19669256 DOI: 10.1007/s12072-008-9049-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
85 Li M, Zhou ZH, Sun XH, Zhang X, Zhu XJ, Jin SG, Jiang Y, Gao YT, Li CZ, Gao YQ. The dynamic changes of circulating invariant natural killer T cells during chronic hepatitis B virus infection. Hepatol Int 2016;10:594-601. [PMID: 26924524 DOI: 10.1007/s12072-015-9650-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
86 Cassino L, Benetti S, Fay F, Tanno H, Quarleri J. Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. BMC Infect Dis 2011;11:178. [PMID: 21696601 DOI: 10.1186/1471-2334-11-178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
87 Lai CL, Yuen MF. The saga of entecavir. Hepatol Int 2009;3:421-4. [PMID: 19669247 DOI: 10.1007/s12072-009-9138-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
88 Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425-33. [PMID: 19669245 DOI: 10.1007/s12072-009-9140-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 6.6] [Reference Citation Analysis]
89 Gish RG. Improving outcomes for patients with chronic hepatitis B. Curr Gastroenterol Rep. 2007;9:14-22. [PMID: 17335673 DOI: 10.1007/s11894-008-0016-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
90 Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, Zhao J, Duan Z, Jia J, Tang H, Sheng J, Peng J, Lu F, Xie Q, Wei L; Chinese Society of Hepatology, Chinese Medical Association., Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol 2017;5:297-318. [PMID: 29226097 DOI: 10.14218/JCTH.2016.00019] [Cited by in Crossref: 109] [Cited by in F6Publishing: 59] [Article Influence: 27.3] [Reference Citation Analysis]
91 张权, 程明亮, 刘琴, 穆茂, 张影影, 刘碧芸. 恩替卡韦对核苷初治HBeAg阳性慢性乙型肝炎患者的疗效. 世界华人消化杂志 2009; 17(27): 2846-2849 [DOI: 10.11569/wcjd.v17.i27.2846] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
92 Inoue T, Tanaka Y. Hepatitis B virus and its sexually transmitted infection - an update. Microb Cell 2016;3:420-37. [PMID: 28357379 DOI: 10.15698/mic2016.09.527] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
93 Shi H, Huang M, Lin G, Li X, Wu Y, Jie Y, Chong Y. Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA. Biomed Res Int 2016;2016:6725073. [PMID: 27034945 DOI: 10.1155/2016/6725073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
94 Orito E, Fujiwara K, Kanie H, Ban T, Yamada T, Hayashi K. Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients. World J Gastroenterol 2012; 18(39): 5570-5575 [PMID: 23112549 DOI: 10.3748/wjg.v18.i39.5570] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
95 扈晓宇, 杜云, 范昕建, 刘光伟, 钟森. 疏肝健脾中药对替比夫定治疗HBeAg阳性慢性乙型肝炎抗病毒疗效及肌酸激酶的影响. 世界华人消化杂志 2011; 19(21): 2279-2284 [DOI: 10.11569/wcjd.v19.i21.2279] [Reference Citation Analysis]
96 Abbott WG, Tsai P, Leung E, Trevarton A, Ofanoa M, Hornell J, Gane EJ, Munn SR, Rodrigo AG. Associations between HLA class I alleles and escape mutations in the hepatitis B virus core gene in New Zealand-resident Tongans. J Virol 2010;84:621-9. [PMID: 19846510 DOI: 10.1128/JVI.01471-09] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
97 Li X, Jin Q, Zhang H, Jing X, Ding Z, Zhou H, Zhang Z, Yan D, Li D, Gao P, Niu J. Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B. Exp Ther Med 2017;13:1169-75. [PMID: 28450959 DOI: 10.3892/etm.2017.4065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
98 Mealing S, Ghement I, Hawkins N, Scott DA, Lescrauwaet B, Watt M, Thursz M, Lampertico P, Mantovani L, Morais E, Bregman B, Cucherat M. The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. Syst Rev 2014;3:21. [PMID: 24602249 DOI: 10.1186/2046-4053-3-21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
99 Krastev ZA. The “return” of hepatitis B. World J Gastroenterol 2006; 12(44): 7081-7086 [PMID: 17131468 DOI: 10.3748/wjg.v12.i44.7081] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
100 Osborn M. Hepatitis B in HIV: available treatment options and approach to therapy. Curr Infect Dis Rep 2009;11:407-13. [PMID: 19698285 DOI: 10.1007/s11908-009-0057-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
101 Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients? World J Gastroenterol 2012; 18(33): 4604-4609 [PMID: 22969236 DOI: 10.3748/wjg.v18.i33.4604] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
102 Wani MA, Sodhi JS, Yatoo GN, Shah A, Geelani S, Zargar SA, Gulzar GM, Khan M, Aziz SA. Clinical Profile and Efficacy of Antivirals in Hepatitis B Virus Reactivation, in Patients With Cancer Receiving Chemotherapy. J Clin Exp Hepatol 2020;10:590-8. [PMID: 33311896 DOI: 10.1016/j.jceh.2020.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Takemura N, Sugawara Y, Tamura S, Makuuchi M. Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci. 2007;52:2472-2477. [PMID: 17805972 DOI: 10.1007/s10620-006-9656-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
104 Kim DY, Kim JH, Tak WY, Yeon JE, Lee JH, Yoon JH, Lee YJ, Lee BS, Han BH, Lee HC. Baracle® vs Baraclude® for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety. Drug Des Devel Ther 2017;11:3145-52. [PMID: 29184389 DOI: 10.2147/DDDT.S149199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Zeng YL, Qin L, Wei WJ, Cai H, Yu XF, Zhang W, Wu XL, Liu XB, Chen WM, You P, Hong MZ, Liu Y, Dong X, Shia BC, Niu JJ, Pan JS. Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy. Sci Rep 2021;11:3253. [PMID: 33547384 DOI: 10.1038/s41598-021-82939-1] [Reference Citation Analysis]
106 Zimmerman KA, Fischer KP, Joyce MA, Tyrrell DL. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol. 2008;82:8013-8021. [PMID: 18524822 DOI: 10.1128/jvi.00366-08] [Cited by in Crossref: 64] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
107 Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Reference Citation Analysis]
108 Sandhu P, Haque M, Humphries-Bickley T, Ravi S, Song J. Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies. Front Immunol 2017;8:436. [PMID: 28450868 DOI: 10.3389/fimmu.2017.00436] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
109 Shang J, Wang H, Sun J, Fan Z, Huang F, Zhang Y, Jiang Q, Dai M, Xu N, Lin R. A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience. Bone Marrow Transplant. 2016;51:581-586. [PMID: 26752138 DOI: 10.1038/bmt.2015.328] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
110 Marzio DHD, Hann HW. Then and now: The progress in hepatitis B treatment over the past 20 years. World J Gastroenterol 2014; 20(2): 401-413 [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
111 Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol. 2013;48:999-1005. [PMID: 23338486 DOI: 10.1007/s00535-012-0742-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
112 Maklad S, Reyad EM, William EA, Abouzeid A. Efficacy and Safety of Entecavir 0. 5 mg in Treating Naive Chronic Hepatitis B Virus Patients in Egypt: Five Years of Real Life Experience. Gastroenterology Res 2018;11:138-44. [PMID: 29707081 DOI: 10.14740/gr965w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
113 Osborn MK. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag 2009;5:789-98. [PMID: 19851526 DOI: 10.2147/tcrm.s5318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
114 Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatol Int. 2008;2:244-249. [PMID: 19669311 DOI: 10.1007/s12072-008-9045-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
115 Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46:556-564. [PMID: 21246383 DOI: 10.1007/s00535-010-0367-5] [Cited by in Crossref: 106] [Cited by in F6Publishing: 90] [Article Influence: 10.6] [Reference Citation Analysis]
116 Cheng Z, Lin P, Cheng N. HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases. Front Med (Lausanne) 2021;8:713981. [PMID: 34676223 DOI: 10.3389/fmed.2021.713981] [Reference Citation Analysis]
117 Tompa DR, Immanuel A, Srikanth S, Kadhirvel S. Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. Int J Biol Macromol 2021;172:524-41. [PMID: 33454328 DOI: 10.1016/j.ijbiomac.2021.01.076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
118 Suzuki F, Arase Y, Suzuki Y, Akuta N, Sezaki H, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S. Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. J Gastroenterol. 2012; Feb 24. [Epub ahead of print]. [PMID: 22361865 DOI: 10.1007/s00535-012-0548-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
119 Kapoor R, Kottilil S. Strategies to eliminate HBV infection. Future Virol 2014;9:565-85. [PMID: 25309617 DOI: 10.2217/fvl.14.36] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
120 Kawanaka M, Nishino K, Nakamura J, Oka T, Urata N, Goto D, Suehiro M, Kawamoto H, Kudo M, Yamada G. Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy. Liver Cancer. 2014;3:41-52. [PMID: 24804176 DOI: 10.1159/000343857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
121 Colombo GL, Gaeta GB, Viganò M, Di Matteo S. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res 2011;3:37-46. [PMID: 21935331 DOI: 10.2147/CEOR.S16655] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
122 Wilson EM, Tang L, Kottilil S. Eradication Strategies for Chronic Hepatitis B Infection. Clin Infect Dis 2016;62 Suppl 4:S318-25. [PMID: 27190322 DOI: 10.1093/cid/ciw044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
123 Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2006;66:1605-122; discussion 1605-122;. [PMID: 16956310 DOI: 10.2165/00003495-200666120-00009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
124 You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Li YL, Lei H, Liu J, Chen HY, Tang BZ. Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. BMC Infect Dis. 2008;8:123. [PMID: 18803883 DOI: 10.1186/1471-2334-8-123] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
125 Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19(37): 6278-6283 [PMID: 24115827 DOI: 10.3748/wjg.v19.i37.6278] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
126 Conly J, Johnston B. Treatment options for hepatitis B. Can J Infect Dis Med Microbiol 2007;18:173-6. [PMID: 18923722 DOI: 10.1155/2007/464652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
127 Lee HW, Kwon JC, Oh IS, Chang HY, Cha YJ, Choi IS, Kim HJ. Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response. Antimicrob Agents Chemother 2015;59:5348-56. [PMID: 26100697 DOI: 10.1128/AAC.01017-15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
128 Yoshida K, Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy. Int J Mol Sci 2021;22:1456. [PMID: 33535672 DOI: 10.3390/ijms22031456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014; 20(20): 6262-6278 [PMID: 24876747 DOI: 10.3748/wjg.v20.i20.6262] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 82] [Article Influence: 12.1] [Reference Citation Analysis]
130 Yoshida K, Matsuzaki K, Murata M, Yamaguchi T, Suwa K, Okazaki K. Clinico-Pathological Importance of TGF-β/Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis. Cancers (Basel) 2018;10:E183. [PMID: 29874844 DOI: 10.3390/cancers10060183] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
131 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Srivastava M, Singh N, Dixit VK, Nath G, Jain AK. Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study. Indian J Med Res 2016;144:424-32. [PMID: 28139541 DOI: 10.4103/0971-5916.198674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
133 Komatsu H, Inui A, Fujisawa T. Pediatric hepatitis B treatment. Ann Transl Med 2017;5:37. [PMID: 28251116 DOI: 10.21037/atm.2016.11.52] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
134 Yip TC, Lai JC, Wong GL. Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same? J Gastroenterol 2020;55:1023-36. [PMID: 32974760 DOI: 10.1007/s00535-020-01726-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Vallet-Pichard A, Pol S. Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal. Therap Adv Gastroenterol. 2014;7:148-155. [PMID: 25057295 DOI: 10.1177/1756283x14524614] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
136 Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int. 2010;4:414-422. [PMID: 20305760 DOI: 10.1007/s12072-009-9162-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
137 Leemans W, Janssen H, de Man R. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol 2007; 13(18): 2554-2567 [PMID: 17552002 DOI: 10.3748/wjg.v13.i18.2554] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
138 Ahn SH, Kim DH, Lee AR, Kim BK, Park YK, Park ES, Ahn SH, Shin GC, Park S, Kang HS, Rhee JK, Yang SI, Chong Y, Kim KH. Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance. PLoS One 2015;10:e0136728. [PMID: 26322642 DOI: 10.1371/journal.pone.0136728] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
139 Chen Y, Zhao Z, Fan H, Li Z, He Y, Liu C. Safety and therapeutic effects of anti-fibrotic Traditional Chinese Medicine Fuzheng Huayu on persistent advanced stage fibrosis following 2 years entecavir treatment: Study protocol for a single arm clinical objective performance criteria trial. Contemp Clin Trials Commun 2020;19:100601. [PMID: 32642592 DOI: 10.1016/j.conctc.2020.100601] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Kim SR, Yang J, Kudo M, Hino O. Recent advances in the management of chronic hepatitis B. Hepat Mon 2011;11:601-11. [PMID: 22140383 DOI: 10.5812/kowsar.1735143x.657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
141 Hwang JA, Kim KB, Yang MJ, Lim SG, Hwang JC, Cheong JY, Cho SW, Kim SS. Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients. Clin Mol Hepatol 2015;21:131-40. [PMID: 26157750 DOI: 10.3350/cmh.2015.21.2.131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
142 Wu YL, Shen CL, Chen XY. Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis. World J Clin Cases 2019; 7(14): 1784-1794 [PMID: 31417924 DOI: 10.12998/wjcc.v7.i14.1784] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
143 Cheong XK, Wong Z, Nor NM, Lee BR. "Black box warning" rash with entecavir - case report. BMC Gastroenterol 2020;20:305. [PMID: 32948126 DOI: 10.1186/s12876-020-01452-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int. 2009;3:5-15. [PMID: 19763714 DOI: 10.1007/s12072-009-9149-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
145 Hall S, Howell J, Visvanathan K, Thompson A. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses 2020;12:E934. [PMID: 32854335 DOI: 10.3390/v12090934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
146 Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, de Man RA, Yu M, Llamoso C, Tang H. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol 2015; 21(15): 4644-4651 [PMID: 25914474 DOI: 10.3748/wjg.v21.i15.4644] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
147 Choung BS, Kim IH, Jeon BJ, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG. Long-term treatment efficacy and safety of clevudine therapy in naïve patients with chronic hepatitis B. Gut Liver. 2012;6:486-492. [PMID: 23170155 DOI: 10.5009/gnl.2012.6.4.486] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
148 齐有涛, 左维泽. 恩替卡韦联合苦参素治疗e抗原阳性慢性乙型肝炎的荟萃分析. 世界华人消化杂志 2013; 21(15): 1432-1436 [DOI: 10.11569/wcjd.v21.i15.1432] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
149 Sarin SK, Kumar M. Should chronic HBV infected patients with normal ALT treated: debate. Hepatol Int 2008;2:179-84. [PMID: 19669302 DOI: 10.1007/s12072-008-9065-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
150 Zhou Y, Hu C, Yuan G, Liu J, Ren Y, Tang C, Yang S, Dai L, Li Y, Yang D. [Antiviral and antifibrotic therapies reduce occurrence of hepatocellular carcinoma in patients with chronic hepatitis B and liver fibrosis: a 144-week prospective cohort study]. Nan Fang Yi Ke Da Xue Xue Bao 2019;39:633-40. [PMID: 31270040 DOI: 10.12122/j.issn.1673-4254.2019.06.02] [Reference Citation Analysis]
151 Hu Y, Tang L, Zhu Z, Meng H, Chen T, Zhao S, Jin Z, Wang Z, Jin G. A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model. J Transl Med. 2020;18:112. [PMID: 32131853 DOI: 10.1186/s12967-020-02275-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
152 Ali S, Mealing S, Hawkins N, Lescrauwaet B, Bjork S, Mantovani L, Lampertico P. The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients. BMJ Open 2013;3:e001309. [PMID: 23355658 DOI: 10.1136/bmjopen-2012-001309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
153 Xing T, Xu H, Cao L, Ye M. HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis. PLoS One 2017;12:e0169444. [PMID: 28107377 DOI: 10.1371/journal.pone.0169444] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
154 Tan L, Sun Y, Zhu L, Lei X, Liang D, Rao N, Su F, Chen K, Li S. Risk factors of catheter-related thrombosis in early-stage breast cancer patients: a single-center retrospective study. Cancer Manag Res 2019;11:8379-89. [PMID: 31571994 DOI: 10.2147/CMAR.S212375] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
155 Michalak TI, Zhang H, Churchill ND, Larsson T, Johansson NG, Oberg B. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother. 2009;53:3803-3814. [PMID: 19564357 DOI: 10.1128/aac.00263-09] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
156 Yu Y, Hou J, Omata M, Wang Y, Li L. Loss of HBsAg and antiviral treatment: from basics to clinical significance. Hepatol Int 2014;8:39-54. [PMID: 26202405 DOI: 10.1007/s12072-013-9495-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
157 Yamada R, Hiramatsu N, Oze T, Morishita N, Harada N, Yakushijin T, Iio S, Doi Y, Yamada A, Kaneko A. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol. 2015;50:785-794. [PMID: 25384794 DOI: 10.1007/s00535-014-1010-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
158 Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008;26:937-49. [PMID: 18850763 DOI: 10.2165/00019053-200826110-00006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
159 Chung GE, Lee JH, Kim YJ. Does antiviral therapy reduce complications of cirrhosis? World J Gastroenterol 2014; 20(23): 7306-7311 [PMID: 24966601 DOI: 10.3748/wjg.v20.i23.7306] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
160 Ishikawa T. Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2013; 19(47): 8861-8866 [PMID: 24379608 DOI: 10.3748/wjg.v19.i47.8861] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
161 Llovet JM, Lok A. Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1121-3. [PMID: 18695130 DOI: 10.1093/jnci/djn261] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
162 Shindo M, Chayama K, Mochida S, Toyota J, Tomita E, Kumada H, Yokosuka O, Sata M, Hayashi N, Suzuki K, Okanoue T, Tsubouchi H, Ishikawa H, Seriu T, Omata M. Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial. Hepatol Int 2009;3:445-52. [PMID: 19669249 DOI: 10.1007/s12072-009-9135-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
163 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 660] [Article Influence: 77.2] [Reference Citation Analysis]
164 Gao L, Trinh HN, Li J, Nguyen MH. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther 2014;39:629-37. [PMID: 24467455 DOI: 10.1111/apt.12629] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
165 He LT, Ye XG, Zhou XY. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients. World J Gastroenterol 2016; 22(46): 10210-10218 [PMID: 28028369 DOI: 10.3748/wjg.v22.i46.10210] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
166 Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol 2015; 7(11): 1541-1552 [PMID: 26085913 DOI: 10.4254/wjh.v7.i11.1541] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
167 Wu D, Wang P, Han M, Chen Y, Chen X, Xia Q, Yan W, Wan X, Zhu C, Xie Q, Jiang J, Wei L, Tan D, Dou X, Yu Y, Hou J, Luo X, Ning Q. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatol Int. 2019;13:573-586. [PMID: 31172415 DOI: 10.1007/s12072-019-09956-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
168 Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8:275-284. [PMID: 21423260 DOI: 10.1038/nrgastro.2011.33] [Cited by in Crossref: 171] [Cited by in F6Publishing: 165] [Article Influence: 17.1] [Reference Citation Analysis]
169 Yuen MF, Lee SH, Kang HM, Kim CR, Kim J, Ngai V, Lai CL. Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice. Antimicrob Agents Chemother 2009;53:1779-85. [PMID: 19223649 DOI: 10.1128/AAC.01290-08] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
170 Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: Recommendations for a standardized approach. Gastroenterology. 2008;134:405-415. [PMID: 18242209 DOI: 10.1053/j.gastro.2007.11.036] [Cited by in Crossref: 163] [Cited by in F6Publishing: 151] [Article Influence: 11.6] [Reference Citation Analysis]
171 Thio CL, Smeaton L, Hollabaugh K, Saulynas M, Hwang H, Saravanan S, Kulkarni S, Hakim J, Nyirenda M, Iqbal HS, Lalloo UG, Campbell TB, Lockman S, Currier JS. Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. AIDS 2015;29:1173-82. [PMID: 26035319 DOI: 10.1097/QAD.0000000000000686] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
172 Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, Zheng MH, Tang H, Feng P. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci. 2010;55:2373-2380. [PMID: 20512414 DOI: 10.1007/s10620-010-1257-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 5.2] [Reference Citation Analysis]
173 Hsu CW, Liang KH, Lin CL, Wang TH, Yeh CT. Platelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors. BMC Infect Dis 2017;17:9. [PMID: 28056849 DOI: 10.1186/s12879-016-2121-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
174 Kim CW, Kim CS, Kim HY, Lee CD, Yu K, Llamoso C, Lee HJ. Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B. Korean J Intern Med 2018;33:91-101. [PMID: 29228519 DOI: 10.3904/kjim.2016.111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist. 2011;4:55-64. [PMID: 21694909 DOI: 10.2147/idr.s4188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
176 Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, Xu D, Liu J, Xu D, Llamoso C. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int. 2008;2:486-493. [PMID: 19669324 DOI: 10.1007/s12072-008-9088-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
177 Wong VW, Wong GL, Tse CH, Yuen LK, Chan HY, Locarnini SA, Chan HL. Antiviral drug resistance testing in patients with chronic hepatitis B. Dig Dis Sci. 2012;57:221-231. [PMID: 21743991 DOI: 10.1007/s10620-011-1816-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
178 Ji TT, Tan N, Lu HY, Xu XY, Yu YY. Early renal injury indicators can help evaluate renal injury in patients with chronic hepatitis B with long-term nucleos(t)ide therapy. World J Clin Cases 2020; 8(24): 6306-6314 [PMID: 33392311 DOI: 10.12998/wjcc.v8.i24.6306] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Lingala S, Lau DT, Koh C, Auh S, Ghany MG, Hoofnagle JH. Long-term lamivudine therapy in chronic hepatitis B. Aliment Pharmacol Ther 2016;44:380-9. [PMID: 27375283 DOI: 10.1111/apt.13707] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
180 Niederau C. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014; 20(33): 11595-11617 [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
181 De Clercq E, Férir G, Kaptein S, Neyts J. Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses 2010;2:1279-305. [PMID: 21994680 DOI: 10.3390/v2061279] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
182 Song JC, Min BY, Kim JW, Kim JY, Kim YM, Shin CM, Lee SH, Hwang JH, Jeong SH, Kim N. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. Korean J Hepatol. 2011;17:268-273. [PMID: 22310791 DOI: 10.3350/kjhep.2011.17.4.268] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
183 Xi ZF, Xia Q. Recent advances in prevention of hepatitis B recurrence after liver transplantation. World J Gastroenterol 2015; 21(3): 829-835 [PMID: 25624716 DOI: 10.3748/wjg.v21.i3.829] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
184 Hara Y, Tokodai K, Nakanishi C, Miyagi S, Kawagishi N. Spontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis B core antibody positive graft: a case report. Surg Case Rep. 2016;2:118. [PMID: 27797067 DOI: 10.1186/s40792-016-0246-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
185 Han SH, Reddy KR, Keeffe EB, Soldevila-Pico C, Gish R, Chung RT, Degertekin B, Lok A; NIH HBV OLT Study Group. Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clin Transplant 2011;25:E152-62. [PMID: 21077950 DOI: 10.1111/j.1399-0012.2010.01349.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
186 Fahrtash-Bahin F, Kariyawasam VC, Gray T, Byth K, George J, Douglas MW. Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World J Gastroenterol 2013; 19(5): 721-726 [PMID: 23430314 DOI: 10.3748/wjg.v19.i5.721] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
187 Glickman MS, Sawyers CL. Converting cancer therapies into cures: lessons from infectious diseases. Cell 2012;148:1089-98. [PMID: 22424221 DOI: 10.1016/j.cell.2012.02.015] [Cited by in Crossref: 122] [Cited by in F6Publishing: 111] [Article Influence: 13.6] [Reference Citation Analysis]
188 Lu HY, Zhuang LW, Yu YY, Ivan H, Si CW, Zeng Z, Li J, Hou DM, Chen XY, Han ZH, Chen Y. Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol 2007; 13(20): 2878-2882 [PMID: 17569128 DOI: 10.3748/wjg.v13.i20.2878] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
189 Park JW, Kwak KM, Kim SE, Jang MK, Suk KT, Kim DJ, Park SH, Lee MS, Kim HS, Park CK. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients. BMC Gastroenterol 2017;17:39. [PMID: 28279168 DOI: 10.1186/s12876-017-0596-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
190 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283X12450245] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
191 Bhattacharya D, Thio CL. Review of hepatitis B therapeutics. Clin Infect Dis. 2010;51:1201-1208. [PMID: 20954965 DOI: 10.1086/656624] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.1] [Reference Citation Analysis]
192 Lee S, Park JY, Song K, Kim DY, Kim BK, Kim SU, Ku HJ, Han KH, Ahn SH. Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. Gut Liver 2015;9:776-83. [PMID: 25963085 DOI: 10.5009/gnl14297] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
193 Tillmann HL. The treatment of chronic hepatitis B: Focus on adefovir-like antivirals. Ther Clin Risk Manag 2008;4:797-802. [PMID: 19209262 DOI: 10.2147/tcrm.s1965] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
194 Sagnelli C, Sagnelli E. Towards the worldwide eradication of hepatitis B virus infection: A combination of prophylactic and therapeutic factors. World J Clin Infect Dis 2019; 9(2): 11-22 [DOI: 10.5495/wjcid.v9.i2.11] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
195 Fung J, Lai CL, Yuen MF. Management of chronic hepatitis B in severe liver disease. World J Gastroenterol 2014; 20(43): 16053-16061 [PMID: 25473157 DOI: 10.3748/wjg.v20.i43.16053] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
196 Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, Yurdaydin C. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 2012;13:663-76. [PMID: 22815098 DOI: 10.1007/s10198-012-0413-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
197 Moon JC, Kim SH, Kim IH, Lee CH, Kim SW, Lee SO, Lee ST, Kim DG. Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy. Gut Liver. 2015;9:395-404. [PMID: 25473072 DOI: 10.5009/gnl14170] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
198 Şahin A, Namıduru M, Balkan A, Karaoğlan İ, Gülşen MT. Assessment of histopathological alterations in patients with chronic hepatitis B infection following long-term oral antiviral therapy. Saudi Med J 2018;39:999-1005. [PMID: 30284582 DOI: 10.15537/smj.2018.10.23056] [Reference Citation Analysis]
199 Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14(45): 6902-6910 [PMID: 19058323 DOI: 10.3748/wjg.14.6902] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
200 Zhou P, Yang F, Wang J, Mao R, Qi X, Huang Y, Zhang J. Improved Efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients. Medicine (Baltimore) 2015;94:e730. [PMID: 25929904 DOI: 10.1097/MD.0000000000000730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
201 Ataei B, Khodadoostan M, Pouria B, Adibi P. Tenofovir in treatment of Iranian patients with chronic hepatitis B virus infection: An open-label case series. J Res Pharm Pract 2016;5:166-70. [PMID: 27512706 DOI: 10.4103/2279-042X.185714] [Reference Citation Analysis]
202 Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010;55:2727-2734. [PMID: 20238245 DOI: 10.1007/s10620-010-1179-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 6.0] [Reference Citation Analysis]
203 Chen WC, Cheng JS, Chiang PH, Tsay FW, Chan HH, Chang HW, Yu HC, Tsai WL, Lai KH, Hsu PI. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy. PLoS One. 2015;10:e0131545. [PMID: 26121480 DOI: 10.1371/journal.pone.0131545] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
204 Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. Int J Med Sci. 2013;10:427-433. [PMID: 23471472 DOI: 10.7150/ijms.5472] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
205 de Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ, Ono SK. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol 2020;55:496-514. [PMID: 32185517 DOI: 10.1007/s00535-020-01680-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
206 Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Krüger W, Mousset S, Neuburger S, Neumann S, Penack O, Silling G, Vehreschild JJ, Einsele H, Maschmeyer G; Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation). Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol 2016;95:1435-55. [PMID: 27339055 DOI: 10.1007/s00277-016-2711-1] [Cited by in Crossref: 106] [Cited by in F6Publishing: 80] [Article Influence: 21.2] [Reference Citation Analysis]
207 Seo HY, Lee HA, Ko SY, Wang JH, Kim JH, Choe WH, Kwon SY. Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B. Clin Mol Hepatol 2017;23:154-9. [PMID: 28479588 DOI: 10.3350/cmh.2016.0067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
208 Sun IO, Hong YA, Park HS, Choi SR, Chung BH, Park CW, Yang CW, Kim YS, Choi BS. Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. Korean J Intern Med 2012;27:411-6. [PMID: 23269882 DOI: 10.3904/kjim.2012.27.4.411] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
209 Ide T, Sata M, Chayama K, Shindo M, Toyota J, Mochida S, Tomita E, Kumada H, Yamada G, Yatsuhashi H, Hayashi N, Ishikawa H, Seriu T, Omata M. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. Hepatol Int 2010;4:594-600. [PMID: 21063482 DOI: 10.1007/s12072-010-9185-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
210 Reijnders JG, LA Janssen H. New approaches in the management of chronic hepatitis B: role of tenofovir. Infect Drug Resist 2009;2:13-26. [PMID: 21694884 DOI: 10.2147/idr.s3918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
211 Forde KA, Tanapanpanit O, Reddy KR. Hepatitis B and C in African Americans: current status and continued challenges. Clin Gastroenterol Hepatol 2014;12:738-48. [PMID: 23811241 DOI: 10.1016/j.cgh.2013.06.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
212 Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007; 13(31): 4264-4267 [PMID: 17696259 DOI: 10.3748/wjg.v13.i31.4264] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
213 Choi MS, Yoo BC. Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines. Gut Liver 2010;4:15-24. [PMID: 20479908 DOI: 10.5009/gnl.2010.4.1.15] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
214 Shamliyan TA, Johnson JR, MacDonald R, Shaukat A, Yuan JM, Kane RL, Wilt TJ. Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med 2011;26:326-39. [PMID: 21203860 DOI: 10.1007/s11606-010-1569-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
215 Du QW, Ding JG, Sun QF, Hong L, Cai FJ, Zhou QQ, Wu YH, Fu RQ. Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study. Med Sci Monit. 2013;19:751-756. [PMID: 24019010 DOI: 10.12659/msm.889443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
216 Song JE, Lee CH, Kim BS. Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice. Korean J Intern Med. 2019;34:802-810. [PMID: 30959583 DOI: 10.3904/kjim.2019.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
217 程笑, 汪莉萍, 韩方正, 庞亚博, 黄姜伟. 聚乙二醇干扰素α-2a对慢性乙型肝炎患者外周血单个核细胞表面IFNGR1的影响. 世界华人消化杂志 2017; 25(19): 1743-1749 [DOI: 10.11569/wcjd.v25.i19.1743] [Reference Citation Analysis]
218 Buti M, Oyagüez I, Lozano V, Casado MA. Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B: a systematic review. Pharmacoeconomics. 2013;31:63-75. [PMID: 23329593 DOI: 10.1007/s40273-012-0009-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
219 Lim JK, Chang AY, Zaman A, Martin P, Fernandez-Rodriguez CM, Korkmaz M, Rossi S, Ford JM, Noonan T, Cooney E, Navarro V, Colombato L. Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. J Clin Transl Hepatol 2020;8:377-84. [PMID: 33447520 DOI: 10.14218/JCTH.2020.00039] [Reference Citation Analysis]
220 Yeh ML, Huang CF, Huang CI, Dai CY, Lin IH, Liang PC, Hsieh MH, Lin ZY, Chen SC, Huang JF, Chen JJ, Yu ML, Chuang WL. Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. PLoS One 2019;14:e0220663. [PMID: 31393964 DOI: 10.1371/journal.pone.0220663] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
221 Shaikh T, Cooper C. Reassessing the role for lamivudine in chronic hepatitis B infection: a four-year cohort analysis. Can J Gastroenterol 2012;26:148-50. [PMID: 22408765 DOI: 10.1155/2012/936259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
222 Kim JH, Sinn DH, Kim K, Kim H, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut Liver 2016;10:939-47. [PMID: 27282264 DOI: 10.5009/gnl15527] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
223 Suh DJ, Um SH, Herrmann E, Kim JH, Lee YS, Lee HJ, Lee MS, Lee YJ, Bao W, Lopez P. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. Antimicrob Agents Chemother. 2010;54:1242-1247. [PMID: 20028815 DOI: 10.1128/aac.01163-09] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
224 Nishikawa H, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T, Osaki Y. Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy. Oncol Lett. 2013;6:1213-1218. [PMID: 24179497 DOI: 10.3892/ol.2013.1578] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
225 Lee KS, Kweon YO, Um SH, Kim BH, Lim YS, Paik SW, Heo J, Lee HJ, Kim DJ, Kim TH, Lee YS, Byun KS, Kim D, Lee MS, Yu K, Suh DJ. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Clin Mol Hepatol 2017;23:331-9. [PMID: 28946736 DOI: 10.3350/cmh.2016.0040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
226 Yu S, Luo H, Pan M, Luis AP, Xiong Z, Shuai P, Zhang Z. Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. Int J Clin Pharm 2016;38:1035-43. [PMID: 27450506 DOI: 10.1007/s11096-016-0358-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
227 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
228 Audsley J, Seaberg EC, Sasadeusz J, Matthews GV, Avihingsanon A, Ruxrungtham K, Fairley K, Finlayson R, Hwang HS, Littlejohn M, Locarnini S, Dore GJ, Thio CL, Lewin SR. Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART. PLoS One 2011;6:e26482. [PMID: 22069454 DOI: 10.1371/journal.pone.0026482] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
229 Karayiannis P. Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) 2012;2012:478631. [PMID: 24278700 DOI: 10.6064/2012/478631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
230 Tawada A, Kanda T, Imazeki F, Yokosuka O. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int 2016;10:574-93. [PMID: 27026375 DOI: 10.1007/s12072-016-9720-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
231 Cho JY, Sohn W, Sinn DH, Gwak GY, Paik YH, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. Korean J Intern Med 2017;32:636-46. [PMID: 27809454 DOI: 10.3904/kjim.2016.096] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
232 Chen MF, Lin Y, Xia YC, Sun C, Feng XM, Lu MJ, Yang DL, Wu J. Establishment and application of hepatitis B virus persistent replication model in IFNAR(-/-) mouse. J Huazhong Univ Sci Technolog Med Sci. 2013;33:392-397. [PMID: 23771666 DOI: 10.1007/s11596-013-1130-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
233 Lau G, Marcellin P, Peters M. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol Int 2007;1:316-25. [PMID: 19669356 DOI: 10.1007/s12072-007-9006-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
234 Tsai TY, Huang MT, Sung PS, Peng CY, Tao MH, Yang HI, Chang WC, Yang AS, Yu CM, Lin YP, Bau CY, Huang CJ, Pan MH, Wu CY, Hsiao CD, Yeh YH, Duan S, Paulson JC, Hsieh SL. SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection. J Clin Invest 2021;131:141965. [PMID: 34060491 DOI: 10.1172/JCI141965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
235 Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. J Gastroenterol. 2013;48:930-941. [PMID: 23065021 DOI: 10.1007/s00535-012-0688-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
236 Nam JY, Lee JH. Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice? Clin Mol Hepatol 2017;23:311-3. [PMID: 29198095 DOI: 10.3350/cmh.2017.0069] [Reference Citation Analysis]
237 Sohn HR, Min BY, Song JC, Seong MH, Lee SS, Jang ES, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW. Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infect Dis. 2014;14:439. [PMID: 25125320 DOI: 10.1186/1471-2334-14-439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
238 Robotin MC, George J. Community-based hepatitis B screening: what works? Hepatol Int 2014;8:478-92. [PMID: 25298848 DOI: 10.1007/s12072-014-9562-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
239 Zhang Y, Wang YT, Luo JX, Hu XY, Yang F, Lin W, Liang X, Zhao BJ, Zhang S, Chen YY. Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20-30 Times the ULN). Evid Based Complement Alternat Med 2019;2019:7260369. [PMID: 30949222 DOI: 10.1155/2019/7260369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
240 Hsu CW, Chen YC, Chang ML, Lin CC, Lin SM, Chen WT, Chu YD, Yeh CT. Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients. Open Forum Infect Dis 2018;5:ofx271. [PMID: 29362723 DOI: 10.1093/ofid/ofx271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
241 Takkenberg B, de Bruijne J, Weegink C, Jansen P, Reesink H. Novel therapies in hepatitis B and C. Curr Gastroenterol Rep 2008;10:81-90. [PMID: 18417047 DOI: 10.1007/s11894-008-0013-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
242 Perrillo R, Buti M, Durand F, Charlton M, Gadano A, Cantisani G, Loong CC, Brown K, Hu W, Lopez-Talavera JC. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl. 2013;19:887-895. [PMID: 23788462 DOI: 10.1002/lt.23690] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
243 Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: What’s the future holding for us? World J Gastroenterol 2015; 21(44): 12558-12575 [PMID: 26640332 DOI: 10.3748/wjg.v21.i44.12558] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
244 Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Ray Kim W, Mannalithara A, Trinh H, Chu D, Tran T, Min A, Do S, Te H, Reddy KR, Lok AS. Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. Aliment Pharmacol Ther 2016;43:134-44. [PMID: 26510638 DOI: 10.1111/apt.13440] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
245 Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B: Lamivudine resistance. Hepatol Int. 2008;2:440-456. [PMID: 19669319 DOI: 10.1007/s12072-008-9105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
246 Gupta N, Goyal M, Wu CH, Wu GY. The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. J Clin Transl Hepatol. 2014;2:202-211. [PMID: 26357626 DOI: 10.14218/jcth.2014.00021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
247 Kim SS, Cheong JY, Cho SW. Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver 2011;5:278-87. [PMID: 21927654 DOI: 10.5009/gnl.2011.5.3.278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
248 Ahn SH, Chun JY, Shin SK, Park JY, Yoo W, Hong SP, Kim SO, Han KH. Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B. Clin Mol Hepatol 2013;19:399-408. [PMID: 24459645 DOI: 10.3350/cmh.2013.19.4.399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
249 Schiffer JT, Swan DA, Stone D, Jerome KR. Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach. PLoS Comput Biol. 2013;9:e1003131. [PMID: 23861664 DOI: 10.1371/journal.pcbi.1003131] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
250 Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J;  Chronic Hepatitis B Study Consortium. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016;65:313-320. [PMID: 25586058 DOI: 10.1136/gutjnl-2014-308546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 12.0] [Reference Citation Analysis]
251 Dakin H, Sherman M, Fung S, Fidler C, Bentley A. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. Pharmacoeconomics 2011;29:1075-91. [PMID: 22077579 DOI: 10.2165/11589260-000000000-00000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
252 Lee JH, Cho Y, Lee DH, Lee M, Yoo JJ, Choi WM, Cho YY, Lee YB, Yu SJ, Yoon JH. Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance. Antimicrob Agents Chemother. 2014;58:1730-1737. [PMID: 24395227 DOI: 10.1128/aac.02483-13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
253 Noordeen F, Scougall CA, Grosse A, Qiao Q, Ajilian BB, Reaiche-Miller G, Finnie J, Werner M, Broering R, Schlaak JF, Vaillant A, Jilbert AR. Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection. PLoS One. 2015;10:e0140909. [PMID: 26560490 DOI: 10.1371/journal.pone.0140909] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
254 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 12.1] [Reference Citation Analysis]
255 Kim HS, Yim HJ, Jang MK, Park JW, Suh SJ, Seo YS, Kim JH, Kim BH, Park SJ, Lee SH, Kim SG, Kim YS, Lee JI, Lee JW, Kim IH, Kim TY, Kim JW, Jeong SH, Jung YK, Park H, Group SGHOBOARS. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol 2015; 21(38): 10874-10882 [PMID: 26478678 DOI: 10.3748/wjg.v21.i38.10874] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
256 Abaalkhail F, Elsiesy H, AlOmair A, Alghamdi MY, Alalwan A, AlMasri N, Al-Hamoudi W; Saudi Association for the Study of Liver Diseases and Transplantation (SASLT). SASLT practice guidelines for the management of hepatitis B virus. Saudi J Gastroenterol 2014;20:5-25. [PMID: 24496154 DOI: 10.4103/1319-3767.126311] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
257 Guo R, Xie Y, Yang J, Lu H, Ye P, Jin L, Lin W. Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment. Sci Rep 2019;9:5916. [PMID: 30976044 DOI: 10.1038/s41598-019-42421-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
258 Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat 2012;19:377-86. [PMID: 22571899 DOI: 10.1111/j.1365-2893.2012.01602.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 88] [Article Influence: 9.3] [Reference Citation Analysis]
259 Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 10.4] [Reference Citation Analysis]
260 Fu LL, Liu J, Chen Y, Wang FT, Wen X, Liu HQ, Wang MY, Ouyang L, Huang J, Bao JK. In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy. Cell Prolif. 2014;47:326-335. [PMID: 24965018 DOI: 10.1111/cpr.12117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
261 Jiang Y, Li W, Yu L, Liu J, Xin G, Yan H, Sun P, Zhang H, Xu D, Niu J. Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies. Cell Mol Immunol. 2011;8:75-82. [PMID: 20921939 DOI: 10.1038/cmi.2010.37] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
262 Sasadeusz J, Audsley J, Mijch A, Baden R, Caro J, Hunter H, Matthews G, McMahon MA, Olender SA, Siliciano RF. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS. 2008;22:947-955. [PMID: 18453854 DOI: 10.1097/qad.0b013e3282ffde91] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
263 Barnes E. Therapeutic vaccines in HBV: lessons from HCV. Med Microbiol Immunol 2015;204:79-86. [PMID: 25573348 DOI: 10.1007/s00430-014-0376-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
264 Lee KJ, Choe BH, Choe JY, Kim JY, Jeong IS, Kim JW, Yang HR, Chang JY, Kim KM, Moon JS, Ko JS. A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B. J Korean Med Sci 2018;33:e63. [PMID: 29441755 DOI: 10.3346/jkms.2018.33.e63] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
265 Zoulim F, Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med. 2015;5. [PMID: 25833942 DOI: 10.1101/cshperspect.a021501] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 15.3] [Reference Citation Analysis]
266 Ndugga N, Lightbourne TG, Javaherian K, Cabezas J, Verma N, Barritt AS 4th, Bataller R. Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. BMJ Open 2017;7:e013620. [PMID: 28336739 DOI: 10.1136/bmjopen-2016-013620] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
267 Ward H, Tang L, Poonia B, Kottilil S. Treatment of hepatitis B virus: an update. Future Microbiol. 2016;11:1581-1597. [PMID: 27855500 DOI: 10.2217/fmb-2016-0128] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
268 Deng YR, Yoshida K, Jin QL, Murata M, Yamaguchi T, Tsuneyama K, Moritoki Y, Niu JQ, Matsuzaki K, Lian ZX. Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. Clin Exp Immunol 2014;176:102-11. [PMID: 24372395 DOI: 10.1111/cei.12259] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
269 Heo NY. Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign? Clin Mol Hepatol 2017;23:125-7. [PMID: 28669139 DOI: 10.3350/cmh.2017.0106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
270 Kwon DH, Kim IH, Choung BS, Ahn DS, Yoo SH, Park SB, Lee S, Kim SH, Kim SW, Im YJ. Continuous long-term entecavir therapy in naïve chronic hepatitis B patients showing partial virologic response. Gut Liver 2013;7:712-8. [PMID: 24312713 DOI: 10.5009/gnl.2013.7.6.712] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
271 Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, Jiang J, Xie Q, Dou X, Sun Y, Li Y, Liu Y, Liu G, Mao D, Chi X, Tang H, Li X, Xie Y, Chen X, Jiang J, Zhao P, Hou J, Gao Z, Fan H, Ding J, Zhang D, Ren H. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol 2018;6:25-34. [PMID: 29577029 DOI: 10.14218/JCTH.2017.00072] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 9.7] [Reference Citation Analysis]
272 Maier M, Liebert UG, Wittekind C, Kaiser T, Berg T, Wiegand J. Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B. PLoS One. 2013;8:e67481. [PMID: 23826307 DOI: 10.1371/journal.pone.0067481] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
273 Liang J, Jiang MJ, Deng X, Xiao Zhou X. Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study. Hepat Mon. 2013;13:e7862. [PMID: 24032045 DOI: 10.5812/hepatmon.7862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
274 Li X, Jin Q, Xu H, Zhang Z, Zhou H, Yan D, Li D, Gao P, Niu J. Chronic hepatitis B patients with high liver fibrosis levels should receive antiviral treatment. Exp Ther Med 2017;13:3624-30. [PMID: 28588691 DOI: 10.3892/etm.2017.4422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
275 Liu CJ, Chen PJ. Elimination of Hepatitis B in Highly Endemic Settings: Lessons Learned in Taiwan and Challenges Ahead. Viruses 2020;12:E815. [PMID: 32731536 DOI: 10.3390/v12080815] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
276 Jo YJ, Kim KA, Lee JS, Kim NH, Bae WK, Song TJ, Kim JW. Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir. Korean J Intern Med 2015;30:170-6. [PMID: 25750558 DOI: 10.3904/kjim.2015.30.2.170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
277 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3] [Cited by in Crossref: 636] [Cited by in F6Publishing: 661] [Article Influence: 48.9] [Reference Citation Analysis]
278 Abbas Z, Siddiqui AR. Management of hepatitis B in developing countries. World J Hepatol 2011; 3(12): 292-299 [PMID: 22216369 DOI: 10.4254/wjh.v3.i12.292] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
279 Qu J, Yu Z, Li Q, Chen Y, Xiang D, Tan L, Lei C, Bai W, Li H, Shang Q, Chen L, Hu X, Lu W, Li Z, Chen D, Wang X, Zhang C, Xiao G, Qi X, Chen J, Zhou L, Chen G, Li Y, Zeng Z, Rong G, Dong Z, Chen Y, Lou M, Wang C, Lu Y, Zhang C, Yang Y. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial. Trials. 2014;15:438. [PMID: 25381721 DOI: 10.1186/1745-6215-15-438] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
280 Ouyang Y, Fu X, Peng S, Tan D, Fu L. Plasma miR-146a predicts serological conversion of hepatitis B e-antigen (HBeAg) in chronic hepatitis B patients treated with nucleotide analogs. Ann Transl Med 2019;7:449. [PMID: 31700885 DOI: 10.21037/atm.2019.08.72] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
281 Takayama H, Komura T, Kagaya T, Sugimoto S, Orita N, Asahina Y, Nishikawa M, Ohta H, Kaneko S, Unoura M. Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B. Can J Gastroenterol Hepatol 2021;2021:3259833. [PMID: 34422709 DOI: 10.1155/2021/3259833] [Reference Citation Analysis]
282 Kim SR, Yang J, Kudo M, Hino O. Recent advances in the management of chronic hepatitis B. Hepat Mon 2011;11:601-11. [PMID: 22140383 DOI: 10.5812/kowsar.1735143x.657] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
283 Ghany MG, Feld JJ, Chang KM, Chan HLY, Lok ASF, Visvanathan K, Janssen HLA. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. Lancet Gastroenterol Hepatol 2020;5:406-17. [PMID: 32057301 DOI: 10.1016/S2468-1253(19)30344-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
284 Yue-Meng W, Yang LH, Yang JH, Xu Y, Yang J, Song GB. The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure. Hepatol Int. 2016;10:462-469. [PMID: 26482576 DOI: 10.1007/s12072-015-9667-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
285 Lei T, Tan F, Hou Z, Liu P, Zhao X, Liu H. Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib. Front Oncol 2020;10:596500. [PMID: 33552970 DOI: 10.3389/fonc.2020.596500] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
286 Jung HJ, Ho MJ, Ahn S, Han YT, Kang MJ. Synthesis and Physicochemical Evaluation of Entecavir-Fatty Acid Conjugates in Reducing Food Effect on Intestinal Absorption. Molecules 2018;23:E731. [PMID: 29565327 DOI: 10.3390/molecules23040731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
287 Aoki J, Kimura K, Kakihana K, Ohashi K, Sakamaki H. Efficacy and tolerability of Entecavir for hepatitis B virus infection after hematopoietic stem cell transplantation. Springerplus. 2014;3:450. [PMID: 25184113 DOI: 10.1186/2193-1801-3-450] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
288 Al-Mahtab M, Bazinet M, Vaillant A. Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection. PLoS One. 2016;11:e0156667. [PMID: 27257978 DOI: 10.1371/journal.pone.0156667] [Cited by in Crossref: 97] [Cited by in F6Publishing: 86] [Article Influence: 19.4] [Reference Citation Analysis]
289 Enomoto M, Nishiguchi S, Tamori A, Kobayashi S, Sakaguchi H, Shiomi S, Kim SR, Enomoto H, Saito M, Imanishi H. Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. J Gastroenterol. 2013;48:397-404. [PMID: 22850869 DOI: 10.1007/s00535-012-0645-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
290 Nakagawa H, Maeda S. Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Patholog Res Int 2012;2012:172894. [PMID: 22666632 DOI: 10.1155/2012/172894] [Cited by in Crossref: 33] [Cited by in F6Publishing: 44] [Article Influence: 3.7] [Reference Citation Analysis]
291 Ridruejo E. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. World J Gastroenterol 2014; 20(23): 7169-7180 [PMID: 24966587 DOI: 10.3748/wjg.v20.i23.7169] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
292 Nagao Y. The role of dentists in controlling hepatocellular carcinoma in Japan (Review). Exp Ther Med 2021;21:113. [PMID: 33335576 DOI: 10.3892/etm.2020.9545] [Reference Citation Analysis]
293 Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49:S174-S184. [PMID: 19399794 DOI: 10.1002/hep.22900] [Cited by in Crossref: 142] [Cited by in F6Publishing: 140] [Article Influence: 11.8] [Reference Citation Analysis]
294 Yotsuyanagi H, Koike K. Drug resistance in antiviral treatment for infections with hepatitis B and C viruses. J Gastroenterol 2007;42:329-35. [PMID: 17530355 DOI: 10.1007/s00535-007-2034-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
295 Manne V, Gochanour E, Kowdley KV. Current perspectives into the evaluation and management of hepatitis B: a review. Hepatobiliary Surg Nutr 2019;8:361-9. [PMID: 31489305 DOI: 10.21037/hbsn.2019.02.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
296 郑俊福, 韩大康, 李丽, 罗晓岚, 肖默, 卢实春, 闾军. 恩替卡韦联合乙肝免疫球蛋白预防肝移植术后乙肝再感染. 世界华人消化杂志 2009; 17(7): 716-719 [DOI: 10.11569/wcjd.v17.i7.716] [Reference Citation Analysis]
297 Gupta S, Altice FL. Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications. J Urban Health 2009;86:263-79. [PMID: 19184447 DOI: 10.1007/s11524-008-9338-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
298 Lenci I, Milana M, Grassi G, Manzia TM, Gazia C, Tisone G, Angelico R, Baiocchi L. Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger? World J Gastroenterol 2020; 26(18): 2166-2176 [PMID: 32476783 DOI: 10.3748/wjg.v26.i18.2166] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
299 Kang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. World J Gastroenterol 2014; 20(23): 7207-7212 [PMID: 24966590 DOI: 10.3748/wjg.v20.i23.7207] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
300 Min JS, Kwon S, Jin YH. SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System. Biomedicines 2021;9:996. [PMID: 34440200 DOI: 10.3390/biomedicines9080996] [Reference Citation Analysis]
301 Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res. 2015;121:69-81. [PMID: 26112647 DOI: 10.1016/j.antiviral.2015.06.014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 8.3] [Reference Citation Analysis]
302 Choi HN, Song JE, Lee HC, Jo HH, Lee CH, Kim BS. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir. Clin Mol Hepatol 2015;21:24-31. [PMID: 25834799 DOI: 10.3350/cmh.2015.21.1.24] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
303 Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV therapy. Viruses 2009;1:484-509. [PMID: 21994557 DOI: 10.3390/v1030484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
304 Abaalkhail FA, Al-Hamoudi WK, Khathlan A, Alghamdi S, Alghamdi M, Alqahtani SA, Sanai FM. SASLT practice guidelines for the management of Hepatitis B virus - An update. Saudi J Gastroenterol 2021;27:115-26. [PMID: 33976009 DOI: 10.4103/sjg.sjg_539_20] [Reference Citation Analysis]
305 Nguyen LH, Hoang J, Nguyen NH, Vu VD, Wang C, Trinh HN, Li J, Zhang JQ, Nguyen MH. Ethnic differences in incidence of hepatitis B surface antigen seroclearance in a real-life multicenter clinical cohort of 4737 patients with chronic hepatitis B infection. Aliment Pharmacol Ther 2016;44:390-9. [PMID: 27363288 DOI: 10.1111/apt.13709] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
306 Tajiri K, Shimizu Y. New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol 2016; 8(21): 863-873 [PMID: 27478536 DOI: 10.4254/wjh.v8.i21.863] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
307 Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13(30): 4085-4090 [PMID: 17696226 DOI: 10.3748/wjg.v13.i30.4085] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
308 Yu SK, Kwon OS, Jung HS, Bae KS, Kwon KA, Kim YK, Kim YS, Kim JH. Influence of transforming growth factor-beta1 gene polymorphism at codon 10 on the development of cirrhosis in chronic hepatitis B virus carriers. J Korean Med Sci. 2010;25:564-569. [PMID: 20357999 DOI: 10.3346/jkms.2010.25.4.564] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
309 Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistance. Hepatol Int 2008;2:440-56. [PMID: 19669319 DOI: 10.1007/s12072-008-9105-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
310 Dienstag JL, Wei LJ, Xu D, Kreter B. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig 2007;27:35-49. [PMID: 17177578 DOI: 10.2165/00044011-200727010-00003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
311 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15(20): 2489-2499 [PMID: 19468999 DOI: 10.3748/wjg.15.2489] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
312 Gane EJ. The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int. 2008;2:304-307. [PMID: 19669258 DOI: 10.1007/s12072-008-9083-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
313 Ali L, Idrees M, Ali M, Rehman IU, Hussain A, Afzal S, Butt S, Saleem S, Munir S, Badar S. An overview of treatment response rates to various anti-viral drugs in Pakistani hepatitis B virus infected patients. Virol J 2011;8:20. [PMID: 21235813 DOI: 10.1186/1743-422X-8-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
314 Lai K, Zhang C, Ke W, Gao Y, Zhou S, Liu L, Yang Y. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China. Clin Drug Investig 2017;37:233-47. [PMID: 27928739 DOI: 10.1007/s40261-016-0486-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
315 Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Kitahara S, Hashimoto S, Kawabe N, Harata M, Nitta Y, Murao M, Nakano T, Shimazaki H, Arima Y, Suzuki K, Yoshioka K. Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. J Gastroenterol. 2011;46:1324-1334. [PMID: 21822591 DOI: 10.1007/s00535-011-0444-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
316 Li Q, Chen L, Zhou Y. Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy. Clin Exp Med 2018;18:273-82. [PMID: 29350286 DOI: 10.1007/s10238-018-0486-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
317 Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680-1686. [PMID: 19632234 DOI: 10.1053/j.gastro.2009.07.047] [Cited by in Crossref: 125] [Cited by in F6Publishing: 94] [Article Influence: 10.4] [Reference Citation Analysis]
318 Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 125-140 [PMID: 17206760 DOI: 10.3748/wjg.v13.i1.125] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
319 Korshed P, Li L, Liu Z, Wang T. The Molecular Mechanisms of the Antibacterial Effect of Picosecond Laser Generated Silver Nanoparticles and Their Toxicity to Human Cells. PLoS One 2016;11:e0160078. [PMID: 27575485 DOI: 10.1371/journal.pone.0160078] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
320 Zhang X, An Y, Jiang X, Xu M, Xu L, Chen S, Xi Y. Entecavir versus Lamivudine therapy for patients with chronic hepatitis B-associated liver failure: a meta-analysis. Hepat Mon 2014;14:e19164. [PMID: 25598786 DOI: 10.5812/hepatmon.19164] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
321 Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga N, Takahashi S, Ochi H, Nelson Hayes C, Ginba H, Matsuyama K, Kawakami H, Chayama K. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol. 2013;48:1188-1204. [PMID: 23397114 DOI: 10.1007/s00535-012-0737-2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
322 Jin X, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One. 2012;7:e34198. [PMID: 22479562 DOI: 10.1371/journal.pone.0034198] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
323 Hagiwara S, Nishida N, Kudo M. Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon. World J Hepatol 2015; 7(23): 2427-2431 [PMID: 26483864 DOI: 10.4254/wjh.v7.i23.2427] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
324 Suzuki Y, Yotsuyanagi H, Okuse C, Nagase Y, Takahashi H, Moriya K, Suzuki M, Koike K, Iino S, Itoh F. Fatal liver failure caused by reactivation of lamivudine-resistant hepatitis B virus: A case report. World J Gastroenterol 2007; 13(6): 964-969 [PMID: 17352033 DOI: 10.3748/wjg.v13.i6.964] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
325 Kim YW, Kwon JH, Chung E, Lee SW, Lee JY, Jang JW, Chung KW, Nam SW. Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma. Gastroenterol Res Pract 2015;2015:181065. [PMID: 25878659 DOI: 10.1155/2015/181065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
326 Guo R, Mao H, Hu X, Zheng N, Yan D, He J, Yang J. Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment. Sci Rep 2016;6:37015. [PMID: 27845395 DOI: 10.1038/srep37015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
327 Park JY, Heo J, Lee TJ, Yim HJ, Yeon JE, Lim YS, Seo MJ, Ahn SH, Lee MS. A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. PLoS One 2013;8:e57900. [PMID: 23536775 DOI: 10.1371/journal.pone.0057900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]